Botulinum toxin A for post-stroke spasticity: Insights from the French National Hospital Discharge Database (2015–2023)
BoNT-A remains underutilized in the treatment of post-stroke spasticity in France. These results emphasize the need to enhance access to and adherence to BoNT-A therapy to optimize post-stroke spasticity management.
Authors
- Pierre Karam (ORCID: https://orcid.org/0000-0002-0631-8541)
- Anne Forestier
- Djamel Bensmaïl (ORCID: https://orcid.org/0000-0001-9360-9330)
- Jean-Yves Loze
Institutions
- Inserm (FR)
- Ipsen (France) (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris-Saclay (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Raymond-Poincaré (FR)
Publication Details
- Journal
- European Stroke Journal
- Published
- 2025-09-19
- DOI
- https://doi.org/10.1177/23969873251374771
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00